Advertisement


Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib

2015 IASLC World Conference on Lung Cancer

Advertisement

Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 33.03, 33.06, 33.07).



Related Videos

Lung Cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a c...

Lung Cancer

Philip Bonomi, MD, on SBRT and Surgery for Localized Disease

Philip Bonomi, MD, of Rush Medical College, summarizes a debate on two important issues: choosing between surgery and stereotactic body radiation therapy (SBRT) in operable NSCLC, ...

Lung Cancer

Lorraine Cheryl Pelosof, MD, PhD, on Never-Smokers in NSCLC

Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with n...

Lung Cancer

Everett E. Vokes, MD, on Controversies in Stage IIIA Disease

Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality cho...

Lung Cancer

Vassiliki Papadimitrakopoulou, MD, on The Lung MAP Clinical Trial

Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerat...

Advertisement

Advertisement



Advertisement